274 related articles for article (PubMed ID: 27665129)
1. Mitigating Cocrystal Physical Stability Liabilities in Preclinical Formulations.
Bhardwaj S; Lipert M; Bak A
J Pharm Sci; 2017 Jan; 106(1):31-38. PubMed ID: 27665129
[TBL] [Abstract][Full Text] [Related]
2. Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.
Lipert MP; Rodríguez-Hornedo N
Mol Pharm; 2015 Oct; 12(10):3535-46. PubMed ID: 26207517
[TBL] [Abstract][Full Text] [Related]
3. Engineering cocrystal solubility, stability, and pH(max) by micellar solubilization.
Huang N; Rodríguez-Hornedo N
J Pharm Sci; 2011 Dec; 100(12):5219-34. PubMed ID: 21910122
[TBL] [Abstract][Full Text] [Related]
4. Characterization and Quality Control of Pharmaceutical Cocrystals.
Izutsu KI; Koide T; Takata N; Ikeda Y; Ono M; Inoue M; Fukami T; Yonemochi E
Chem Pharm Bull (Tokyo); 2016 Oct; 64(10):1421-1430. PubMed ID: 27319284
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical cocrystals and poorly soluble drugs.
Thakuria R; Delori A; Jones W; Lipert MP; Roy L; Rodríguez-Hornedo N
Int J Pharm; 2013 Aug; 453(1):101-25. PubMed ID: 23207015
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical Cocrystal: An Antique and Multifaceted Approach.
Panzade PS; Shendarkar GR
Curr Drug Deliv; 2017; 14(8):1097-1105. PubMed ID: 27758692
[TBL] [Abstract][Full Text] [Related]
7. Oral lipid-based formulations.
Hauss DJ
Adv Drug Deliv Rev; 2007 Jul; 59(7):667-76. PubMed ID: 17618704
[TBL] [Abstract][Full Text] [Related]
8. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5.
Kuminek G; Cao F; Bahia de Oliveira da Rocha A; Gonçalves Cardoso S; Rodríguez-Hornedo N
Adv Drug Deliv Rev; 2016 Jun; 101():143-166. PubMed ID: 27137109
[TBL] [Abstract][Full Text] [Related]
9. Cocrystal formulations: A case study of topical formulations consisting of ferulic acid cocrystals.
Aitipamula S; Das S
Eur J Pharm Biopharm; 2020 Apr; 149():95-104. PubMed ID: 32035236
[TBL] [Abstract][Full Text] [Related]
10. Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization.
Lipert MP; Roy L; Childs SL; Rodríguez-Hornedo N
J Pharm Sci; 2015 Dec; 104(12):4153-4163. PubMed ID: 26390213
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Basis of Cocrystal Dissolution Advantage.
Cao F; Amidon GL; Rodríguez-Hornedo N; Amidon GE
J Pharm Sci; 2018 Jan; 107(1):380-389. PubMed ID: 28989017
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.
Cavanagh KL; Maheshwari C; Rodríguez-Hornedo N
J Pharm Sci; 2018 Jan; 107(1):113-120. PubMed ID: 29097226
[TBL] [Abstract][Full Text] [Related]
13. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
Elder DP; Holm R; Diego HL
Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
[TBL] [Abstract][Full Text] [Related]
14. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamic Solubility Profile of Carbamazepine-Cinnamic Acid Cocrystal at Different pH.
Keramatnia F; Shayanfar A; Jouyban A
J Pharm Sci; 2015 Aug; 104(8):2559-65. PubMed ID: 26096952
[TBL] [Abstract][Full Text] [Related]
16. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
Pouton CW; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Suspension Formulations of Theophylline Cocrystals With Artificial Sweeteners.
Aitipamula S; Wong ABH; Kanaujia P
J Pharm Sci; 2018 Feb; 107(2):604-611. PubMed ID: 28987500
[TBL] [Abstract][Full Text] [Related]
18. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
19. Cocrystal and its Application in the Field of Active Pharmaceutical Ingredients and Food Ingredients.
Wang N; Xie C; Lu H; Guo N; Lou Y; Su W; Hao H
Curr Pharm Des; 2018; 24(21):2339-2348. PubMed ID: 29788878
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical cocrystals: an overview.
Qiao N; Li M; Schlindwein W; Malek N; Davies A; Trappitt G
Int J Pharm; 2011 Oct; 419(1-2):1-11. PubMed ID: 21827842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
